If a malfunction does occur, Stryker warned, it could impact the device's effectiveness. No adverse events have been reported at this time.

Savannah DeMelo, a professional soccer player with Racing Louisville FC, alleges that clinicians failed to properly diagnose and manage her heart disease. She collapsed on the field during a match in September 2025.

The newly approved device is 14% shorter than the previous version and gives clinicians more options when making implant decisions.

Digital twins may be used in the near future to help clinicians plan ahead before EP ablation procedures. They could preview how the patient's heart will react to treatment, for example, increasing the odds of a positive outcome.

Johnson & Johnson is selling key assets related to its Laminar program to a new startup, Jaguar LAA. This comes less than three years after Johnson & Johnson acquired Laminar for $400 million. 

Boston Scientific is warning clinicians about an ongoing safety concern with its LUX-Dx family of insertable cardiac monitors. No devices need to be returned or replaced, but the FDA did finalize a Class II recall. 

It was a relatively small study, and patients were only followed for six months, but these late-breaking data out of ESC Congress 2026 give care teams a lot to consider. 

The therapy, if successful, could eliminate the need for patients to take drugs or undergo invasive catheter ablation procedures.

Clinicians may want to take a more proactive approach when managing PAD patients to ensure they minimize the risk of new-onset atrial fibrillation.